Principal Investigator
Jaime Merchan
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20251011
Clinical Trial Summary
A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 (as Monotherapy or in Combination with Pembrolizumab) in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Prostate, Bladder, and Kidney Cancers
Contact Information
Phone Number
+1 (407) 7659589